Javlor
What Javlor is used for
Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. Efficacy and safety of vinflunine have not been studied in patients with performance status … (the exact criteria are in the official EMA product information).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Javlor
- Active substance
- vinflunine
- Disease area
- Carcinoma, Transitional Cell; Urologic Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01CA05
- Marketing authorisation holder
- Pierre Fabre Medicament
- Authorised in the EU since
- 2009
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Javlor used for?
Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. Efficacy and safety of vinflunine have not been studied in patients with performance status … (the exact criteria are in the official EMA product information).
What is the active substance in Javlor?
Javlor contains vinflunine.
Who makes Javlor?
The EU marketing authorisation holder is Pierre Fabre Medicament.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU